

Prof Gabriel Scally

Visiting Chair at the University of Bristol and the University of the West of England

Total Funding from the Bill & Melinda Gates Foundation at both universities where Professor Scally works is \$19,168,802 of which \$549,972 is for vaccines

<https://www.gatesfoundation.org/search>

Date: August 2007

Purpose: to research and develop a user-friendly low-cost water quality test that can be used on-site in developing country field conditions

Amount: \$13,162,521

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2007/08/OPP48599>

Date: July 2017

Purpose: to describe the transmission dynamics of SP colonization in 2 year old children who receive nasal influenza vaccines and their contacts

Amount: \$549,972

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2017/07/OPP1165787>

Date: October 2011

Purpose: to test the ability of microbial fuel cells to convert urine and sludge into electrical energy while also purifying water by killing disease-causing pathogens in the waste.

Amount: \$100,000

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2011/10/OPP1044458>

Date: October 2013

Purpose: to develop Microbial Fuel Cells into a mature sustainable energy technology with a direct application in everyday life, at or near to the intended use that could change the way people think about energy and human waste

Amount: \$880,787

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2013/10/OPP1094890>

Date: May 2019

Purpose: to support the activities related to development of the microbial fuel cell as a urine and effluent treatment component for use by the world most vulnerable populations and the movement of the technology towards commercialization at a price

Amount: \$1,468,876

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2019/05/OPP1189676>

Date: May 2016

Purpose: To scale down the size and improve the performance of microbial fuel cell (MFC) technology in order to further opportunities to implement this technology to address energy access issues in developing countries

Amount: \$1,763,630

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2016/05/OPP1149065>

Date: September 2020

Purpose: to develop indicators for measuring the resilience to climate change of water and sanitation services in rural communities and small towns in

Bangladesh, Nepal, Ethiopia and Uganda

Amount: \$1,151,866

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2020/09/INV-015713>

Date: April 2017

Purpose: to identify new, more effective family planning methods for Mozambique by collecting data on quantitative beliefs of women to measure the relative importance of factors such as fear of side effects that inhibit contraceptive use

Amount: \$91,150

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2017/04/OPP1171956>

Prof Scally is also Associate fellow at the Institute for Public Policy Research think tank Iprr.org

All funding details can be found at

<https://www.iprr.org/about/how-we-are-funded/>

2019 Annual report shows over 2 million in funding of which 250k came from Astra-Zeneca, Glaxo Smithkline, Pfizer, Johnson & Johnson, Janssen & Gilead

<https://www.ippr.org/files/2021-01/accounts-2019.pdf>

Prof Scally was also Director of the World Health Organization (WHO) Collaborating Centre on Healthy Urban Environments which is attached to the University Of Bristol which is also funded by the Bill & Melinda Gates Foundation (see above)

Prof Sam McConkey

Has received funding from the Wellcome Trust and is a Director of the European Vaccine Initiative (EVI), an organisation whose objective is "to spearhead global vaccine development efforts".

<https://www.rcsi.com/people/profile/smconkey>

European Vaccine Initiative Funding

<https://www.euvaccine.eu/donors>

One of the donors for EVI is The Global Health Technology Fund which has received over \$70 million from the Bill & Melinda Gates Foundation

<https://www.gatesfoundation.org/search>

Date: June 2013

Purpose: to develop new health technologies as a result of funding and development collaborations with Japanese industry and government

Amount: \$63,200,000

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2013/06/OPP1081122>

Date: February 2013

Purpose: to support the systems and documentation needed for the launch of the GHIT Fund

Amount: \$110,000

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2013/02/OPP1083545>

Date: October 2013

Purpose: to develop new drugs for the prevention and treatment of malaria, tuberculosis, Chagas, and visceral leishmaniasis

Amount: \$7,600,000

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2013/10/OPP1096590>

Dr Tomas Ryan

Dr Tomas Ryan is a Neuroscientist and Associate Professor, School Of Biochemistry and Immunology Trinity College Dublin

TCD got funding from the Bill & Melinda Gates foundation for Vaccine development to the tune of \$230,000.

Date: November 2018

Purpose: to increase public awareness about decisive moments in global health, as witnessed by the Norwegian physician Tore Godal

Amount: \$230,000

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2018/11/OPP1198031>

Dr Ryan was also sponsored by Wellcome Trust Sanger Institute to complete his Phd in Cambridge

<https://ryan-lab.org/tomas-ryan/>

Dr Gerry Killeen

Prof Gerry Killeen is the AXA Research Chair in Applied Pathogen Ecology at the School of Biological, Earth and Environmental Sciences.

<http://research.ucc.ie/profiles/D026/gerard.killeen@ucc.ie>

Prior to joining UCC Dr Killeen worked at the Ifakara Health Institute in Tanzania which was funded to the tune of \$11,339,383

<https://www.gatesfoundation.org/search>

Date: October 2019

Purpose: to support basic research on the important malaria vector *Anopheles funestus*

Amount: \$100,000

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2019/10/INV-003929>

Date: February 2020

Purpose: to conduct research on the basic biology and population genetics of the major malaria vector

Anopheles funestus

Amount: \$2,821,000

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2020/02/INV-002138>

Date: August 2020

Purpose: to produce Phase I and Phase II data for evaluation of a new alphacypermethrin-PBO LLIN

Amount: \$250,291

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2020/08/INV-022988>

Date: June 2011

Purpose: to support outdoor vector control devices to complement existing methods

Amount: \$387,822

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2011/06/OPP1035742>

Date: December 2008

Purpose: to demonstrate the mode of action, spatial range, efficacy, user acceptability and cost-effectiveness of spatial repellents for household use

Amount: \$3,299,361

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2008/12/OPP51431>

Date: October 2019

Purpose: to identify the best mosquito control strategies for preventing malaria by developing technology that combines artificial intelligence and infrared spectroscopy to quantify mosquito age and disease transmission potential in real time

Amount: \$100,000

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2019/10/OPP1217647>

Date: November 2020

Purpose: to build capacity for data management and modeling in Tanzania to support the country's National Malaria Control Program, and train modelers to deploy to other malaria-endemic countries

Amount: \$1,465,902

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2020/11/INV-016807>

Date: September 2017

Purpose: to demonstrate local disruption of residual malaria transmission by targeting and eliminating *Anopheles funestus* mosquitoes, by combining innovative techniques that maximize behavioral and physiological susceptibility of the vectors

Amount: \$715,000

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2017/09/OPP1175877>

Date: September 2017

Purpose: to demonstrate successful colonization and genetically characterize *Anopheles funestus* as the major driver of malaria transmission in Eastern and Southern African settings to inform potential novel approaches to large-scale malaria control and elimination efforts

Amount: \$2,000,007

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2017/09/OPP1177156>

Date: May 2009

Purpose: to test the efficacy of a decoy-based malaria vector control model for reducing transmission that targets breeding, resting, and feeding mosquitoes

Amount: \$100,000

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2009/05/OPP53214>

Date: October 2017

Purpose: to deliver medical supplies to remote areas by recruiting local shopkeepers who are able to overcome poor transport infrastructures to regularly travel to central suppliers, also during the rainy seasons, to maintain their own stocks

Amount: \$100,000

<https://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database/Grants/2017/10/OPP1181763>

Prof Patricia Kearney

Professor of Epidemiology UCC

Has received funding from the Wellcome Trust and research grants totalling €13,956,470

<http://publish.ucc.ie/researchprofiles/C010/patriciakearney>